4D Molecular Therapeutics (FDMT) Stock Price, News & Analysis

Company Overview

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Key Stats

• Today's Range: $4.05 to $4.23
• 50-Day Range: $2.78 to $4.79
• 52-Week Range: $2.24 to $28.93
• Volume: 595,805 shs
• Average Volume: 826,597 shs
• Market Capitalization: $191.34 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $29.56
• Consensus Rating: Moderate Buy

4D Molecular Therapeutics Stock Analysis - MarketRank™

4D Molecular Therapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 663rd out of 924 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

4D Molecular Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 7 buy ratings, 2 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

4D Molecular Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for 4D Molecular Therapeutics are expected to decrease in the coming year, from ($2.84) to ($3.34) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of 4D Molecular Therapeutics is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of 4D Molecular Therapeutics is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

4D Molecular Therapeutics has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

10.15% of the float of 4D Molecular Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

4D Molecular Therapeutics has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in 4D Molecular Therapeutics has recently decreased by 6.85%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

4D Molecular Therapeutics does not currently pay a dividend.

Dividend Growth

4D Molecular Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.15% of the float of 4D Molecular Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

4D Molecular Therapeutics has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in 4D Molecular Therapeutics has recently decreased by 6.85%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for FDMT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

2 people have added 4D Molecular Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, 4D Molecular Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.60% of the stock of 4D Molecular Therapeutics is held by insiders.

Percentage Held by Institutions

99.27% of the stock of 4D Molecular Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

FDMT Stock Analysis - Frequently Asked Questions

How have FDMT shares performed this year?

4D Molecular Therapeutics' stock was trading at $5.57 at the beginning of the year. Since then, FDMT stock has decreased by 25.9% and is now trading at $4.13.
View the best growth stocks for 2025 here.

How were 4D Molecular Therapeutics' earnings last quarter?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) issued its quarterly earnings data on Thursday, May, 8th. The company reported ($0.86) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by $0.02. 4D Molecular Therapeutics had a negative trailing twelve-month return on equity of 33.26% and a negative net margin of 767,126.06%.

When did 4D Molecular Therapeutics IPO?

4D Molecular Therapeutics (FDMT) raised $101 million in an IPO on Friday, December 11th 2020. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, Evercore ISI and William Blair served as the underwriters for the IPO and Chardan was co-manager.

Who are 4D Molecular Therapeutics' major shareholders?

4D Molecular Therapeutics' top institutional shareholders include BVF Inc. IL (9.85%), Goldman Sachs Group Inc. (9.00%), Millennium Management LLC (3.53%) and Federated Hermes Inc. (2.70%). Insiders that own company stock include Global Investors Lp Viking, David Kirn, Scott Bizily and Robert Young Kim.
View institutional ownership trends.

How do I buy shares of 4D Molecular Therapeutics?

Shares of FDMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of 4D Molecular Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that 4D Molecular Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 6/22/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:FDMT
• CIK: 1650648
• Web: www.4dmoleculartherapeutics.com
• Phone: 510-505-2680
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $29.56
• High Stock Price Target: $44.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +615.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$160.87 million
• Net Margins: -767,126.06%
• Pretax Margin: -767,126.00%
• Return on Equity: -33.26%
• Return on Assets: -30.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.36
• Quick Ratio: 12.36

Sales & Book Value

• Annual Sales: $40 thousand
• Price / Sales: 4,783.57
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.05 per share
• Price / Book: 0.37

Miscellaneous

• Outstanding Shares: 46,330,000
• Free Float: 41,878,000
• Market Cap: $191.34 million
• Optionable: Optionable
• Beta: 2.84